UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2023

Cognition Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

001-40886

(Primary Standard Industrial Classification Code Number)

2500 Westchester Ave.

Purchase, NY (Address of principal executive offices)

Registrant's telephone number, including area code: (412) 481-2210

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Delaware (State or other jurisdiction of

incorporation or organization)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

		Name of Exchange on Which
Title of Each Class	Trading Symbol	Registered
Common Stock, par value \$0.001 per share	CGTX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

13-4365359 (I.R.S. Employer Identification No.)

10577 (Zip Code)

Item 8.01 Other Events.

Attached as Exhibit 99.1 is a presentation that the Company may use from time to time in presentations or discussions with investors, analysts, and other parties.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.	Document	
<u>99.1</u>	Investor presentation of Cognition Therapeutics, Inc.	
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	
SIGNATURES		
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.		

Date: September 12, 2023

COGNITION THERAPEUTICS, INC.

 By:
 /s/ Lisa Ricciardi

 Name:
 Lisa Ricciardi

 Title:
 President and Chief Executive Officer



Disease-modifying medicines for neurodegenerative disorders

September 2023

Forward-looking Statements

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statement facts or current conditions, including but not limited to, statements regarding our cash, financial resources and product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical re to CT1812 will be replicated in later trials, our clinical development plans, are forward-looking statements. These statements, including tother important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements to be materially different from any future results, performance, or achievements so that we believe from results, performance, or achievements to be materially different from any future results, performance, or achievements so that we believe france, or achievements to a unmeertain or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predic of which are beyond our control. Factors that may cause actual results of infer materially from current expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability to successfully advance our current and future product candidates through development activities, preclinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory film regulatory approval of our

TRADEMARKS

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade referred to in this presentation may be listed without the TM, SM © or ® symbols, but we will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade

MARKET & INDUSTRY DATA

Projections, estimates, industry data and information contained in this presentation, including the size of and growth in key end markets, are based on information from third-party sources and management estimates. Although v party-sources are reliable, we cannot guarantee the accuracy or completeness of these sources. Our management's estimates are derived from third-party sources, publicly available information, our knowledge of our industry ar such information and knowledge. Our management's estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a numble ilmitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to us and our industry's future performance are necessarily subject to a high degree ol a variety of factors, including, but not limited to, those described above, that could cause future performance to differ materially from our expressed projections, estimates and assumptions or those provided by third parties.

Alzheimer's Disease (AD) – It impacts every one of

The people

- 2021 ~ 6.5M Americans
- 2060 ~ 12.7M Americans

The Cost

- 2020 Estimated 11M family members/unpaid caregivers provided 15.3B hours of care at a value of ~\$257B*
- 2050 Anticipated caregiving costs ~ \$1.1 trillion (in 2019 dollars) **

* https://pubmed.ncbi.nlm.nih.gov/33756057/ ** https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures

AD – Finally breakthroughs & the realities of const


- 2 approved mAbs, 1 additional drug filed for approval
 - Annual cost for therapy = \$26K \$28K/ patient
 - Estimated \$5B cost to Medicare for 216K patients on Leqembi
- Diagnostics & treatment considerations
 - 3,600 Infusion centers in the US
 - 2,500 PET scanners in the US performing 2M scans/year
 - 11,900 MRI systems in the US
- The mismatch between demographics, economics and drug availability is unsustainable

* https://hitconsultant.net/2022/12/14/report-the-state-of-cancer-centers-2022/

Cognition Therapeutics – Our Company

- Why we do what we do: Neurodegenerative diseases, particularly Alzheimer disease, impacts every one of us.
- How we address neurodegenerative diseases: We identify neurodegenerative targets and treatments. NIH and Advocacy groups help us cost-effectively de clinical candidates.
- What we offer: CT1812 is a potential oral therapy for Alzheimer's disease an Dementia with Lewy Bodies. We are evaluating clinical, regulatory and bioma programs to assess speed to market
- Changing the paradigm: Oral drug for the treatment of dry AMD; proven abil get to the back of the eye

CGTX Near-term Catalysts



Our approach to neurodegenerative diseases




CT1812 Protects Neurons from Toxic Stresso

Innovative mechanism of action within the established amyloid cascade

- Oral, small molecule ligand of sigma-2 (σ-2) receptor
 - High degree of blood brain barrier penetration, reaches therapeutic target
- Targets oligomers, a pathogenic form of amyloid plaques produced early in AI
- Blocks toxic oligomer binding, displaces bound oligomers -protecting synapse
 - Demonstrated disease-modifying impact on synapses
- · Scalable manufacturing from easily sourced materials, well protected IP


Represents potential breakthrough: Treat Alzheimer's disease with a once daily oral drug, minimize imaging requirements and associated side effects



CT1812 Designed to Protect Neurons and Processes Im Neurodegenerative Disease

 σ -2 is a druggable receptor target

- Robust scientific research has demonstrated target engagement and biological effects of σ-2 modulation
- Backed by *in vitro* studies, behavioral data from *in vivo* animal models and strong preclinical program
- Now in multiple Phase 2 trials
- Science vetted through peerreviewed publications and peerreviewed NIA grant process



Our MoA Video: https://vimeo.com/800999561



Our Trials and Target Product Profile




What We Have Learned From Clinical Trials to

Endpoint of Interest: Result: SNAP CT1812 demonstrated target enga Target engagement SPARC² Anatomical effect Demonstrated effect on slowing br Preliminary cognitive Demonstrated 3+ point difference SHINE-A improvement measured by ADAS-COG ay Day Brain wave patterns normalized ac SEQUEL Neurophysiology multiple measures

- 1. AD/PD[™] 2022 & LaBarbera, et al. Transl Neurodegener 2023
- 2. SPARC results submitted for publication
- 3. Abstract of SEQUEL imaging results submitted for upcoming presentation

13

SHINE Clinical Evidence of Cognitive Benefit




- SHINE interim analysis (n=2 promising evidence:
 - 3-point difference (ADAS-CO(between treated and untreate at Day 185
 - Clinically meaningful magnitu
 - Trend towards slower cognitiv CT1812-treated vs placebo-tre participants

SHINE COG0201 Study (NCT03507790) funded by NIA grant R01AG058660




Phase 2 Study Adults with Mild-to-Moderate DLB --"The most common dementia you have never heard

Conducted in collaboration with Lewy Body Dementia Association & U Miami



STURY Phase 2 Efficacy Study in 540 Adults with *Early* Alzheimer's Disease

Conducted in collaboration with Alzheimer's Clinical Trials Consortium



Our Goal: Develop & Launch Commercially Successful Dementia Di to the Realities of US Healthcare System, Patients and Families


Addresses patient care and caregiver needs and economic burden of treatment

CT1812 – Target profile

- Once-daily oral therapy
- Slows cognitive and functional decline in early/MCI and mild-tomoderate AD including Dementia with Lewy Bodies
- Well tolerated, modest side effect profile for use in aging population
 - Limited potential for ARIA
- · Minimal caregiver burden and costs
 - Routine diagnostics and monitoring requirements
 - No imaging requirements; reduced associated economics

New Mechanisms Being Developed, Creating Poter Market for Combination Use

Successful drugs will address gaps in the market



Gaps in development-stage ca

- Breadth of Indication: AD spect early, MCI, mild and moderate
- · Limited diagnostic exclusions
- Comparable efficacy as measu COG or CDR-SB
- No requirement for PET surveil
- No ARIA or infusion safety cons
- Convenience QD dosing, limite

18

Getting to Goal: Phase 2 Program Informs Phase 3 & Regulato

Robust SNAP, SHINE, SPARC and SEQUEL data to drive program design

Preliminary Phase 3 Considerations

- Enrollment appx 700 1,500 / study
- Global enrollment
 - Randomized 2:1 to CT1812 or placebo
 - Phase 2 results inform duration
- Stratification with concomitant therapy
- Initiate heath economics and outcomes research, pricing research and IRA considerations

Preliminary Biomarker Strategy Consid

- Baseline unbiased analyses of plasma/
 - Phase 1/2
 - SHINE Cohort A
 - SPARC
 - SHINE A / SPARC pooled
 - SEQUEL
- Identified biomarkers of CT1812 target (
- Analyzed SHINE, SHIMMER clinical dar correlation of biomarkers with cognitive
- Now, evaluate prospective study to asse predetermined biomarkers measuring ir on synapse health, neuroinflammation e

Grant Funding Has Provided Substantial Sup

Full Grant Awards by year of Award, significantly support operations



Financial Position

Financials as of June 30, 2023

- Cash and Cash Equivalents: \$37.2 million
- Expected cash runway through third quarter of 2024

Grant funding for CT1812 studies as of June 30, 2023

Preclinical through Phase 2: appx \$171.0 million

\$81.8 million

- Approximate funding used: (\$89.2 million)
- Remaining grant funding:



COGN

Next Steps: Preparations for Phase 3 & Commercialization

- Complete dementia trials: mild-moderate Alzheimer's and DLB
- Progress START study in early Alzheimer's disease
- Conduct KOL panels on dementia product profile for Phase 3 development
- Advance MAGNIFY study in dry AMD
- Initiate research on IRA & pricing impact
- Continue pharma engagement

Mild-to-moderate dementia trials to read out in mid 2024

